NBI05

NBI05 is an experimental cancer immunotherapy currently in the pre-clinical stage of development by Noile-Immune Biotech. While the specific antigen target for NBI05 remains undisclosed, the candidate is part of the company's internal pipeline focused on next-generation CAR-T cell therapies. It likely utilizes Noile-Immune's proprietary PRIME (Proliferation-inducing and migration-enhancing) technology, which involves engineering CAR-T cells to co-express interleukin-7 (IL-7) and C-C motif chemokine ligand 19 (CCL19). This approach is designed to enhance the proliferation, survival, and infiltration of both the therapeutic CAR-T cells and the patient's endogenous immune cells into the immunosuppressive microenvironment of solid tumors.

Other names

NIB105-Noile-Immune-undisclosed-CAR-T cell therapyNIB-105-Noile-Immune-undisclosed-CAR-T cell therapyNIB 105-Noile-Immune-undisclosed-CAR-T cell therapy